Polatuzumab vedotin + Rituximab + CHP (Pola-R-CHP), 6 cycles + 2× rituximab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-POLATUZUMAB-VEDOTIN` `DRUG-RITUXIMAB` `DRUG-CYCLOPHOSPHAMIDE` `DRUG-DOXORUBICIN` `DRUG-PREDNISONE`

ID	`REG-POLA-R-CHP`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Notes

POLARIX trial (NEJM 2022): in IPI ≥2 newly-diagnosed DLBCL, superior 2-year PFS (76.7% vs 70.2% R-CHOP, HR 0.73). Comparable OS (mature data still maturing) and toxicity profile (more PN with polatuzumab but offset by NO vincristine). Becoming the new 1L standard for IPI ≥2 in resourced settings — access in Ukraine is the bottleneck. Vincristine is replaced by polatuzumab (hence "CHP" not "CHOP").

Used By

Contraindications

CI-LVEF-LOW-FOR-ANTHRACYCLINE - CI-LVEF-LOW-FOR-ANTHRACYCLINE

Handbook Chapters

HB-DLBCL-1L - Diffuse large B-cell lymphoma: first-line reasoning

Handbook Questions

HQ-DLBCL-1L-002 - HQ-DLBCL-1L-002

Indication

IND-DLBCL-1L-POLA-R-CHP - IND-DLBCL-1L-POLA-R-CHP

Monitoring

MON-R-CHOP-REGIMEN - MON-R-CHOP-REGIMEN